SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by XBiotech Inc. and Certain Officers and Directors

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that it has commenced an investigation of XBiotech Inc. (“XBiotech” or the “Company”) (NASDAQ: XBIT) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On November 23, 2015, XBiotech announced that its 72-patient study on True Human™ therapeutic antibodies had been compromised; the study did not meet its primary endpoint due to several irregularities, including that 25 patients dropped out before receiving either the drug or placebo, that “14 patients erroneously received either placebo or study drug” and that “33 patients completed the study but failed to receive scheduled DEXA scans, properly complete EORTC evaluation, or both.” Following this news, shares of XBiotech were down more than 30% on intraday trading on November 24, 2015. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/xbiotech-xbit

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.